Canada markets closed

Know Labs, Inc. (KNWN)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.5300+0.1300 (+9.29%)
As of 11:33AM EDT. Market open.
Sign in to post a message.
  • S
    Subba
    Know labs is developing the most innovative technology for measuring many components in the blood stream and their patented portfolio is getting stronger and if they succeed the payoff for the investors will be huge. They are concentrating their strategy to get FDA approval for blood glucose, there is some risk that they may not get the approval for blood glucose. The number of shares traded is very small and many are holding for the potential pay off.
  • t
    tim00mike
    FYI - Rockley Photonics Holdings

    https://twitter.com/IcebergResear/status/1517504787386101761

    Iceberg Research published on Rockley Photonics Holdings (NYSE: RKLY — $456 million), a UK-based startup that is developing biosensors for smartwatches and medical devices. Iceberg wrote that “the company is experiencing technological roadblocks and will soon face a cash crunch and heavy dilution.” Iceberg highlighted long delays by Apple in rolling out similar biosensor technology and cited that a major joint venture partner of Rockley, Hengtong Optic-Electric, was recently sanctioned by the U.S. Department of Commerce. In addition, Rockley signed a “vulture financing” deal with Lincoln Park Capital because of a nearly 50% redemption rate in its SPAC closing process. Rockley is down ~75% since its August 2021 IPO.
  • A
    Anonymous
    I call complete B_S_ on that latest video, ...complete.
    - let's start with the disclaimer at the end: KNWN "...makes no representation or warranty as to the accuracy or completeness of the information contained herein." i think i can stop there but...
    - all apps and video screens seem fake, no aliasing, no flicker, no rough edges, no vignetting. they all seem completely smooth, homogenous and superimposed.
    - "when it sends out frequencies and you're at 80mg/dl, we measure about 970 trillion electrons at the frequency of glucose". sounds all wow and technical except, THERE IS NO SUCH THING. With electrons, I'm measuring a charge (group of electrons, like on a capacitor with plates and dielectric which produces a voltage) or current (moving electrons/electron holes in a wire), and exactly how do you measure electrons "at the frequency of glucose"? complete garbage. but he's got an RF transmitter and receiver on the same side so I think he's measuring RF radio wave power or power density reflected back from the radiated RF transmitter. ...and i can't imagine a "frequency of glucose", he's got to be measuring the frequency or frequency shift of whatever frequency was radiated. I'm guessing it's some ISM band like 2.4GHz or 5GHz.
    - "this is the frequency signature of glucose in my body when I woke up and here's what happened after I ate two donuts". No axis labels, no time domain (?), no frequency domain (?) graphs, nothing, no "frequency signature" of anything. would expect to see harmonics of a "frequency signature", no harmonics. My assumption from a line going up and down is that he is showing a relative blood glucose level over time rise and fall after ingesting two donuts, but what he's saying is not what is being superimposed on the video.
    - just some advice: put the teleprompter further back so it's not so obvious you're reading or better yet, memorize the few lines of word salad you're supposed to be the expert of.
  • J
    Joe
    Very important patent issued to Know Labs. See details here: https://www.knowlabs.co/post/database-foundational-patents
  • m
    marcge81
    Know Labs Announces Successful Results from Pre-Clinical Study Validating Bio-RFID™ Platform Technology

    KNWN
    -1.87%
    Wed, June 9, 2021, 9:00 AM·4 min read

    KNWN
    -1.87%

    Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced successful results from an independent pre-clinical study validating the company’s Bio-RFID™ platform technology.

    Know Labs is developing a novel medical device using the Bio-RFID technology that it expects will be the world’s first non-invasive continuous glucose monitor, making finger sticks and micro-needle monitoring devices obsolete and changing care for the world’s 1.5 billion people with diabetes or pre-diabetes. The successful test of the Bio-RFID technology is an important step toward submission of a diagnostic medical device for FDA approval.

    The purpose of the independent pre-clinical research was to confirm that Know Labs’ Bio-RFID technology is able to precisely and non-invasively measure and identify a variety of analytes in vitro by detecting their unique radio frequency spectral responses.

    - ADVERTISEMENT -

    "In the past, we’ve rarely spoken publicly about our test results," said Phil Bosua, Know Labs CEO. "Our energy has been on our research priorities here in the lab. But now we would like to share what we know is a significant milestone – independent verification from a respected research institution that our Bio-RFID technology works."

    The next phase of testing for the Bio-RFID technology will involve clinical human studies measuring blood glucose non-invasively in the body. Data collected from these studies will be included in materials presented to the FDA in a pre-submission meeting. Subsequent clinical trials will be conducted and submitted in the company’s application to the FDA. Know Labs will provide updates on its regulatory strategy and timeline in the coming months.

    The report detailing the results will be submitted for publication in a peer reviewed journal. Upon publication, the report will be made available.

    About Know Labs, Inc.

    Know Labs, Inc. is a public company whose shares trade under the stock symbol "KNWN." The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a glucose monitor. It will provide the user with real time information on their blood glucose levels. This product will require US Food and Drug Administration approval prior to its introduction to the market.

    Safe Harbor Statement

    This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words "may," "will," "could," "should," "would," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2020, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company u
  • N
    Nollie
    I am very interested in KnowLabs and doing some due diligence I came across this company that is making a similar product https://www.diamontech.de/home is somebody able to explain the differences between the 2 companies? Advantages/Disadvantages... thank you
    DiaMonTech :: Non-Invasive Glucose Measurement
    www.diamontech.de
  • O
    Observer
    This stock will be huge just huge. Not many know what they are really developing but I do as I am an early investor met the company people watched it closely. Extraordinary technological development which could change medical monitoring on many levels. Trust me. Good luck
  • L
    L
    ADDITIONAL IP ANNOUNCED TODAY: Know Labs announced it has been granted 3 new patents that support its medical diagnostic focus while also signaling the potential for non-medical applications. These new patents expand Know Labs’ intellectual property portfolio in radio frequency and microwave spectroscopy, further improving its technological position as it readies to launch non-invasive diagnostic devices.

    https://www.businesswire.com/news/home/20210727005341/en/%C2%A0Three-New-Patents-for-Know-Labs-Expand-IP-Portfolio-and-Signal-Further-Applications-for-Bio-RFID%E2%84%A2
    Advancing the development of its proprietary Bio-RFIDTM platform technology while continuing to deliver against its IP strategy, Know Labs, Inc. (OTCQ
    Advancing the development of its proprietary Bio-RFIDTM platform technology while continuing to deliver against its IP strategy, Know Labs, Inc. (OTCQ
    www.businesswire.com
  • C
    Charlie
    "We are building a breakthrough platform technology that will revolutionize medical diagnostics, beginning with what we believe will be the world’s first non-invasive glucose monitoring device," said Phil Bosua, Know Labs CEO and Bio-RFID inventor. "This patent is critical because without the ability to control the timing of the frequency capture, accurate non-invasive measurements using radio frequency on the human body are not possible. We’ve been granted 22 patents to date and have 35 more pending. Our advances will lead to breakthroughs in diagnostics and potentially disease prevention, so we are pursuing and delivering on a disciplined intellectual property strategy to protect our innovative technology and its value."

    U.S. Patent No. 11,033,208 was issued by the United States Patent and Trademark Office and is titled "Fixed Operation Time Frequency Sweeps for an Analyte Sensor." The patent relates to how operation of the Know Labs Bio-RFID sensor technology is controlled. The sensing routines conducted by the sensor to non-invasively detect an analyte in the body are conducted substantially identically to one another, which means results are obtained under as close to identical conditions as possible. This allows for a more accurate comparison between the results of each sensing routine, increasing the precision and accuracy of the Know Labs Bio-RFID sensor technology in non-invasively measuring and identifying a variety of analytes, including glucose.
  • F
    Fuckov
    Tokyo Company Unveils World's First Wearable Glucose MonitorThe wearable provides 24/7 non-invasive needleless monitoring of blood glucose levels. 

    The new wearable uses the company's patented spectrum technology to accurately measure glucose in a person's bloodstream through the skin without having to use a needle.Using the technology, diabetic patients will be able to replace the daily routine of using a needle for measurements with simply strapping on a wristwatch-like wearable device.Eliminating the pain of daily needle use for diabetic patients Quantum Operation is showcasing its new technology at this year's CES alongside a similar oxygen saturation measuring system sensor (SpO2) wearable device.
  • M
    MyN
    Read and weep naysayers

    Today Know Labs announced that we have received approval from an independent Institutional Review Board (IRB) for the protocol of our upcoming internal clinical trial. This brings the company one step closer to an FDA pre-submission meeting and to launching what we believe will be the first non-invasive glucose monitoring devices.

    Testing our non-invasive technology with a larger population is a great opportunity to further validate the technology platform to identify and measure blood glucose levels accurately and non-invasively. The clinical trial will be performed at Know Labs’ new research and development laboratory in Seattle. A news release with further detail on the announcement can be found here.

    Our team will continue to provide updates as further progress is made toward our goal of bringing our non-invasive diagnostic devices to market.
  • A
    Anonymous
    my naysayer comments... "...participants will be taken every five minutes with a Bio-RFID prototype, an Accu-Chek® fingerstick device, and a continuous glucose monitor (CGM)..." I think it will be hard to find anyone, let alone 200 people, that is willing to get a finger stick every 5 minutes for over 2-3 hours, ...and not move. which IRB? is it accredited? i don't see how they claim a MARD of 5.8% when they show raw results 15-20% above and below a CGM result (which already has an error). They must have to average a lot of data and at 5 minutes between data points, even at just 5 readings, that's data that's at least 20 minutes too late for a diabetic. i also wouldn't want to be subjected to RF emissions at zero distance from skin that often. What's the RF power density? Curious to see what numbers they throw up in this 'study'. To me, what they've presented so far seems fudged... even the graph paper lines don't correlate to numbers, looks like just an image background. anything they post seems to be presented in the best possible bias and wording, just doesn't seem convincing to me.
  • M
    Marshawn
    Has anyone come across a potential valuation of the patents awarded to Know Labs for their bio RFID technology platform? Looking at the market value of only Dexcom, which is a market leader for only one single application in medical diagnostics...one could make a pretty bullish case for the market value of their IP.
  • O
    Observer
    Extraordinary upside potential. If you all only knew
  • F
    Fuckov
    "Through internal preliminary testing, Particle, Inc. has confirmed the bulb’s efficacy in disinfecting common germs such as E. coli and Staphylococcus. A world renowned, CDC-regulated biosafety level-4 laboratory is currently testing the Particle bulb’s ability to deactivate SARS-CoV-2, the virus that causes COVID-19."
  • A
    Anonymous
    few questions I couldn't find answers to on their website:

    1. no mention of the word "calibrate". does this product work as an absolute number for blood sugar or relative from a starting point, i.e. do you need to calibrate it with a finger stick (how often)?
    2. the accuracy of the G5 has been eclipsed by the newer G6 with G7 just about to be released; why is there a comparison (today) with, almost a generation and a half, old technology?
    3. it looks like the tests were done on a very stationary person, not moving (at. all.). What is product performance with some arm movement, or even normal activity (like typing) or exertion?
    4. some data on how product works on different arms/people? there's one guy in the video.
    5. i have to doubt "as or better accuracy as the G5": I'm under the assumption normal sugar levels do change smoothly as represented by the underlying G5 curve they show, yet KNWN points jumped above and below. I would expect "more accurate" would at least be as smooth and also be compared to an "actual" or reference number, like a glucose meter. I can't see an accurate number for either in the video.

    The concept is cool and the fact they had a working proof of concept is encouraging, but the fact the test subject didn't move a millimeter during the demo video is most suspect to me.
  • F
    Fuckov
    White paper has been released. Co-authored by Mark Tapshak who helped develop the DexCom device
  • L
    Lawrence
    An influential Biotech advisor informed his readership that he’d sold off a portion of his Know shares for reasons not disclosed - quite possibly simply profit taking or in need of $$ for other investments of course. I actually wouldn’t be surprised if that news by itself triggered a small following sell-off. Apart from that and the general market malaise, there’s been nothing else I’ve seen of note to clearly trigger any sell-off...
  • t
    tim00mike
    Know Labs - Revolutionizing Non-Invasive Medical Diagnostics

    https://www.youtube.com/watch?v=HU7Ee2bLfAs
    Know Labs - Revolutionizing Non-Invasive Medical Diagnostics
    www.youtube.com
  • M
    Mike
    Heading to a conference In PR where Ron Erickson is going to present this Friday